Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have received an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $42.2222.

Several research firms have commented on TEVA. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Truist Financial lifted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings raised shares of Teva Pharmaceutical Industries from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, July 31st. Finally, Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th.

Teva Pharmaceutical Industries Trading Down 0.7%

TEVA opened at $36.53 on Tuesday. The firm has a market cap of $42.57 billion, a price-to-earnings ratio of 60.88, a PEG ratio of 3.93 and a beta of 0.86. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries has a 12 month low of $17.33 and a 12 month high of $37.39. The stock has a fifty day moving average price of $33.59 and a 200-day moving average price of $33.02.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%.The company had revenue of $4.14 billion for the quarter. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries will post 1.96 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the completion of the sale, the executive vice president owned 65,621 shares in the company, valued at approximately $2,237,676.10. This represents a 61.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.54% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. First Bancorp Inc ME acquired a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at about $182,000. X Square Capital LLC acquired a new stake in Teva Pharmaceutical Industries in the second quarter worth about $1,905,000. Victrix Investment Advisors grew its stake in shares of Teva Pharmaceutical Industries by 9.5% during the second quarter. Victrix Investment Advisors now owns 7,850 shares of the company’s stock worth $266,000 after acquiring an additional 681 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Teva Pharmaceutical Industries by 128.1% during the second quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company’s stock worth $103,538,000 after acquiring an additional 1,716,315 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Teva Pharmaceutical Industries by 19.6% during the second quarter. GAMMA Investing LLC now owns 11,361 shares of the company’s stock valued at $385,000 after acquiring an additional 1,859 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.